company background image
FUSN

Fusion Pharmaceuticals NasdaqGS:FUSN Stock Report

Last Price

US$2.27

Market Cap

US$101.6m

7D

6.3%

1Y

-51.7%

Updated

04 Dec, 2022

Data

Company Financials +
FUSN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

FUSN Stock Overview

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines.

Fusion Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Fusion Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.27
52 Week HighUS$8.73
52 Week LowUS$1.98
Beta-0.68
1 Month Change-1.30%
3 Month Change-6.64%
1 Year Change-51.70%
3 Year Changen/a
5 Year Changen/a
Change since IPO-86.65%

Recent News & Updates

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Sep 16

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Aug 29

Recent updates

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Aug 10
Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Jan 16
We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Aug 28
We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

Apr 05
We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Mar 01
How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

Jan 25
Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

Shareholder Returns

FUSNUS BiotechsUS Market
7D6.3%4.2%1.5%
1Y-51.7%-7.4%-14.9%

Return vs Industry: FUSN underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: FUSN underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is FUSN's price volatile compared to industry and market?
FUSN volatility
FUSN Average Weekly Movement12.7%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: FUSN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: FUSN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201483John Vallianthttps://fusionpharma.com

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor.

Fusion Pharmaceuticals Inc. Fundamentals Summary

How do Fusion Pharmaceuticals's earnings and revenue compare to its market cap?
FUSN fundamental statistics
Market CapUS$101.61m
Earnings (TTM)-US$80.23m
Revenue (TTM)US$1.92m

53.1x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FUSN income statement (TTM)
RevenueUS$1.92m
Cost of RevenueUS$53.10m
Gross Profit-US$51.18m
Other ExpensesUS$29.05m
Earnings-US$80.23m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.79
Gross Margin-2,672.79%
Net Profit Margin-4,189.61%
Debt/Equity Ratio18.6%

How did FUSN perform over the long term?

See historical performance and comparison